Visx' phototherapeutic keratectomy (PTK) laser approved in US:
This article was originally published in Clinica
Visx has received US FDA approval to market the Star excimer laser systems (models B and C) for phototherapeutic keratectomy (PTK). Marketing will begin immediately through US partner Alcon Laboratories (see Clinica No 622, p 11). Since international introduction of the streamlined Star system in March, Visx has been gearing up production in readiness for US approval.
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.